# EDGAR Filing Document

**Accession Number:** 0001859807
**File Stem:** 0001213900-26-060879
**Filing Date:** 2026-5
**Character Count:** 12860
**Document Hash:** e72678aa59eeaac305975daab2d8fcd1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-060879.hdr.sgml**: 20260526

**ACCESSION NUMBER**: 0001213900-26-060879

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260522

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260526

**DATE AS OF CHANGE**: 20260526

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Profusa, Inc.
- **CENTRAL INDEX KEY:** 0001859807
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 863437271
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41177
- **FILM NUMBER:** 261017045

**BUSINESS ADDRESS:**
- **STREET 1:** 207 WEST 25TH ST, 9TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10001
- **BUSINESS PHONE:** 212-494-9022

**MAIL ADDRESS:**
- **STREET 1:** 207 WEST 25TH ST, 9TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10001

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NorthView Acquisition Corp
- **DATE OF NAME CHANGE:** 20210429

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): May 22, 2026

**PROFUSA, INC.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-41177** | **86-3437271** |
| (State or other jurisdiction<br> of incorporation) | (Commission File Number) | (IRS Employer<br> Identification No.) |

---

**626 Bancroft Way, Suite A**

**Berkeley, CA 94710**

(Address of principal executive offices, including zip code)

Registrant's telephone number, including area code: (**925) 997-6925**

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, par value $0.0001 per share | PFSA | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 1.01 Entry into a Material Definitive Agreement.**

**First Amendment to Asset Purchase Agreement**

On May 22, 2026, Profusa Inc., a Delaware corporation (the "Company"), and Bio Insights LLC, a limited liability company ("Seller"), entered into a First Amendment to the Asset Purchase Agreement (the "Amendment"), amending that certain Asset Purchase Agreement, dated as of April 21, 2026 (the "Asset Purchase Agreement"), by and between the Company and Seller.

As previously disclosed in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on April 27, 2026, pursuant to the Asset Purchase Agreement, Seller agreed to sell, convey, assign, transfer, and deliver to the Company substantially all of the know-how assets relating to Seller's PanOmics Assay, an integrated, NGS multi-omics analysis platform combining genomics, transcriptomics, metabolomics, and related fields, used in drug discovery and precision medicine (the "Purchased Assets"). The aggregate purchase price under the Asset Purchase Agreement is $30,000,000, to be satisfied through the issuance by the Company to Seller of a newly created series of non-voting preferred stock designated as "Series A Convertible Preferred Stock," convertible into shares of the Company's common stock.

The Amendment deletes Section 4.6 (Management Shares) of the Asset Purchase Agreement in its entirety. Section 4.6 of the Asset Purchase Agreement previously provided that, in connection with the Closing, the Compensation Committee of the board of directors of the Company and the board of directors of the Company would approve and take any action necessary to cause the issuance to management of the Company of an aggregate number of shares of the Company's common stock equal to twelve percent (12%) of the fully diluted shares of the Company's common stock outstanding immediately following the Closing and any related equity financing, for the retention of the Company's Chief Executive Officer and Chief Financial Officer (the "Management Shares"). The Amendment deletes this provision and all references to the Management Shares in the Asset Purchase Agreement.

In addition, the Amendment makes a conforming amendment to Section 3.3(c) of the Asset Purchase Agreement to remove the reference to the Compensation Committee's approval of actions contemplated by Section 4.6.

Except as expressly amended by the Amendment, the Asset Purchase Agreement remains in full force and effect in accordance with its terms.

The foregoing description of the Amendment is not complete and is qualified in its entirety by reference to the full text of the Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

---

| | |
|:---|:---|
| **Exhibit** | **Description** |
| 10.1 | [First Amendment to Asset Purchase Agreement by and between Profusa Inc. and Bio Insights LLC](ea029215101ex10-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| May 26, 2026 | **Profusa, Inc.** | **Profusa, Inc.** |
|  | By: | */s/ Ben Hwang* |
|  | Name: | Ben Hwang |
|  | Title: | Chief Executive Officer |

---

## Exhibit 10.1

**Exhibit 10.1**

**FIRST AMENDMENT TO ASSET PURCHASE AGREEMENT**

This First Amendment to Asset Purchase Agreement (this "**Amendment**") is entered into as of May 22, 2026, by and between **Profusa Inc.**, a Delaware corporation, with its principal place of business at 626 Bancroft Way, Suite A, Berkeley, CA 94710 ("**Buyer**"), and **Bio Insights LLC**, a limited liability company, with its principal place of business at 108 Rotary Drive, Summit, NJ 07901 ("**Seller**," and together with Buyer, the "**Parties**," and each individually, a "**Party**").

**RECITALS**

**WHEREAS**, Buyer and Seller are parties to that certain Asset Purchase Agreement, dated as of April 21, 2026 (the "**Agreement**"), pursuant to which Seller agreed to sell, transfer, assign, convey, and deliver to Buyer substantially all of the know-how assets relating to the PanOmics Platform, and Buyer agreed to purchase and acquire such assets from Seller, on the terms and subject to the conditions set forth therein;

**WHEREAS**, Section 4.6 of the Agreement provides that, in connection with the Closing, the Compensation Committee of the board of directors of Buyer and the board of directors of Buyer will approve and take any action necessary to cause the issuance to management of Buyer of an aggregate number of shares of Buyer's common stock equal to twelve percent (12%) of the fully diluted shares of Buyer's common stock outstanding immediately following the Closing and any related equity financing, for the retention of Buyer's Chief Executive Officer and Chief Financial Officer (the "**Management Shares**");

**WHEREAS**, the Parties desire to amend the Agreement to delete Section 4.6 and all references to the Management Shares, on the terms and subject to the conditions set forth herein; and

**WHEREAS**, Section 11.6 of the Agreement provides that no amendment or modification of the Agreement shall be binding upon any Party unless set forth in a writing duly executed by both Parties.

**AGREEMENT**

**NOW, THEREFORE**, in consideration of the mutual covenants and agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

**ARTICLE 1<br> AMENDMENT**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1 **Deletion of Section 4.6 (Management Shares).** Section 4.6 of the Agreement is hereby deleted in its entirety and replaced with the following:

"Section 4.6 [Reserved.]"

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2 **Deletion of Definition.** The defined term "Management Shares" and all references thereto in the Agreement are hereby deleted and shall be of no further force or effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.3 **Conforming Amendment to Section 3.3(c).** Section 3.3(c) of the Agreement is hereby amended and restated in its entirety to read as follows:

"(c) certified resolutions of the Board of Directors of Buyer evidencing the approval and authorization of the actions contemplated by Section 4.7, in form and substance reasonably satisfactory to Seller;"

**ARTICLE 2<br> MISCELLANEOUS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1 **Effect of Amendment.** Except as expressly amended by this Amendment, the Agreement shall remain in full force and effect in accordance with its terms, and all references therein to "this Agreement" shall be deemed to refer to the Agreement as amended hereby. In the event of any conflict between the terms of this Amendment and the terms of the Agreement, the terms of this Amendment shall control.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2 **Defined Terms.** Capitalized terms used but not otherwise defined in this Amendment shall have the meanings ascribed to such terms in the Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3 **Governing Law.** This Amendment shall be governed by and construed in accordance with the laws of the State of Delaware, without regard to conflicts of laws principles that would result in the application of the laws of any other jurisdiction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.4 **Counterparts.** This Amendment may be executed in two or more counterparts, each of which shall be deemed to be an original but all of which together shall constitute one and the same instrument. The Parties shall be entitled to rely upon delivery of an executed electronic copy of this Amendment, and such executed electronic copy shall be legally effective to create a valid and binding agreement between the Parties.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.5 **Entire Agreement.** This Amendment, together with the Agreement and all schedules, exhibits, and other documents and instruments referred to therein, constitutes the entire agreement between the Parties with respect to the subject matter hereof and supersedes all prior and contemporaneous agreements, negotiations, understandings, representations, and warranties, both written and oral, with respect to such subject matter.

 

*[Remainder of Page Intentionally Blank.]*

 

 

**IN WITNESS WHEREOF**, the Parties have executed this First Amendment to Asset Purchase Agreement as of the date first written above.

---

| | |
|:---|:---|
| **BUYER:** | **BUYER:** |
| **PROFUSA INC.** | **PROFUSA INC.** |
| By: | /s/ Dr. Ben Hwang |
| Name: | Dr. Ben Hwang |
| Title: | Chief Executive Officer |
| **SELLER:** | **SELLER:** |
| **BIO INSIGHTS LLC** | **BIO INSIGHTS LLC** |
| By: | /s/ Dr. Alidad Mireskandari |
| Name: | Dr. Alidad Mireskandari |
| Title: | Managing Partner |

---